ArticleAMB Express2024
Anti-leishmanial activity of Hypericum Scabrum extract against Leishmania major.
Article in AMB Express, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring EGCG for Leishmaniasis: A Natural Strategy for Neglected Disease Intervention.The Yale journal of biology and medicine · 2025Review
- Article
- Therapeutic potential of iron oxide nanoparticles for cutaneous leishmaniasis: a systematic review ofThe journal of venomous animals and toxins including tropical diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Leishmaniasis is a vector-borne disease and one of the most significant neglected tropical diseases. Current anti-leishmanial treatments are often ineffective over extended periods and are associated with toxic side effects, highlighting the urgent need for new, effective, and safe alternative treatments for this infectious disease. The objective of this study was to evaluate the anti-leishmanial effects of a hydroalcoholic extract of Hypericum scabrum (H. scabrum), comparing its efficacy to that of the control drug glucantime against the standard strain of Leishmania major. The H. scabrum plants were collected from the western regions of Iran. A hydroalcoholic extract was prepared from the flower and stem of the plant using a maceration method. High-performance liquid chromatography analysis was conducted to identify the chemical compounds present in the extract. Promastigotes of L. major were cultured, and the anti-leishmanial activity of the extracts was assessed at concentrations ranging from 12.5 to 800 µg/ml using the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay. The half-maximal inhibitory concentration (IC50) values for the H. scabrum plant extract at 24, 48, and 72 h were 245.47, 141.25 and 85.11 μg/ml, respectively. The IC50 values for glucantime (the control drug) at 24 h, 48 h, and 72 h were 30.19, 21.37, and 12.58 μg/ml, respectively. While the H. scabrum extract exhibited a lower effect compared to the control drug, it still demonstrated a significant inhibitory effect on the promastigote form of L. major. Given that the plant extract of H. scabrum has demonstrated promising anti-leishmanial effects against L. major promastigotes, further studies are warranted to evaluate the efficacy of these extracts in animal models of leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.